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Abstract
Background Since receiving a positive recommendation
in England, Wales and Scotland, tocilizumab (TCZ) is one
of the options available to clinicians for the treatment of
rheumatoid arthritis (RA) patients in the UK.
Objective The objective of this study was to evaluate the
cost effectiveness of adding TCZ to the current treatment
sequence of RA patients from a UK payer’s perspective
over a patient lifetime horizon.
Methods An individual sampling model was developed to
synthesise all clinical and economic inputs. Two scenarios
were explored separately: patients contraindicated to
methotrexate (MTX) and those MTX tolerant. For each
scenario, the analysis compared three strategies. The
standard of care (SoC) strategy included a sequence of the
most commonly prescribed biologics; the other two com-
parator strategies considered the addition of TCZ to SoC at
first line and second line. Patient characteristics were rep-
resentative of UK patients. Treatment efficacy and quality-
of-life evidence were synthesised from clinical trials and
secondary sources. An analysis of a patient registry
informed the model parameters regarding treatment dis-
continuation. The safety profile of all treatments in a given
strategy was based on a network meta-analysis and litera-
ture review. Resource utilisation, treatment acquisition,
administration, monitoring and adverse event treatment
costs were considered. All costs reflect 2012 prices.
Uncertainty in model parameters was explored by one-way
and probabilistic sensitivity analysis.
Results In the MTX-contraindicated population, if TCZ
was added to the SoC in first line, the estimated incre-
mental cost-effectiveness ratio (ICER) was £7,300 per
quality-adjusted life-year (QALY) gained; if added in
second line, the estimated ICER was £11,400 per QALY.
In the MTX-tolerant population, the estimated costs and
QALYs of the TCZ strategy were similar to those of the
SoC strategy. Sensitivity analysis showed that parameters
that affect the treatment cost (such as patient weight) can
have a noticeable impact on the overall cost-effectiveness
results. The majority of the other sensitivity analyses
resulted in modest changes to the ICER.
Conclusion For the treatment of RA in MTX-tolerant and
contraindicated patients, the addition of TCZ to the SoC
was estimated to be a cost-effective strategy.
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Key Points for Decision Makers
In methotrexate (MTX)-tolerant patients, the
addition of tocilizumab (TCZ) to the standard
biologic, disease-modifying anti-rheumatic drug,
rheumatoid arthritis treatment sequence in the UK
was associated with similar costs and a modest
improvement in quality of life per patient.
In patients contraindicated to MTX, for whom there
are fewer available treatments, the estimated quality-
of-life benefit was more pronounced.
Overall, the addition of TCZ was estimated to be a
cost-effective strategy, with a lower incremental
cost-effectiveness ratio if used at first compared with
second line.
1 Introduction
Rheumatoid arthritis (RA) is a chronic, progressive and
disabling inflammatory condition typically causing sym-
metrical chronic arthritis characterised by joint pain, stiff-
ness and swelling. It affects approximately 0.5–1 % of the
UK population and affects nearly three times as many
women as men [1]. RA is associated with increased mor-
tality, attributable at least in part to a higher risk of
ischaemic heart disease as well to other factors, including
infections related to co-morbidities, other systemic mani-
festations of the disease and immunosuppressive therapy
[2–4].
Counting its direct, indirect and work-related disability
costs, RA is estimated to cost the UK economy between
£3.8 and £4.75 billion annually [5]. In early RA, these costs
are driven by indirect costs, including the paid employment
forgone by informal caregivers [6, 7]. As RA progresses
and pain, discomfort and physical impairment worsen,
healthcare utilisation and medication costs become the
principal contributors to overall cost [8].
In the absence of a curative treatment for RA, the focus
of RA treatment is currently the prevention or control of
joint damage, minimisation of loss of function and poten-
tial disability, avoidance of pain and improvement of
quality of life (QoL). Certain drugs such as glucocorticoids
and non-steroidal anti-inflammatory drugs (NSAIDs) are
effective in controlling RA symptoms; however, disease-
modifying anti-rheumatic drugs (DMARDs), alone or in
combination, are the mainstay of RA management, and are
used to slow progression of disease and improve function.
They are divided into two categories: synthetic DMARDs
(sDMARDs)—including methotrexate (MTX), lefluno-
mide, sulfasalazine, azathioprine, ciclosporin and hydrox-
ychloroquine—and biologic DMARDs (bDMARDs)—
including abatacept, adalimumab, certolizumab, etaner-
cept, golimumab, infliximab, rituximab and tocilizumab
(TCZ). bDMARDs are licensed for the treatment of RA,
but their use in the UK is currently restricted to patients
who have failed to respond to (or tolerate) at least two
sDMARDs.
An important clinical subgroup encompasses those patients
in whom bDMARDs cannot be given in combination with
MTX [9]. Therefore, this analysis focuses on both combina-
tion treatment as well as biologic monotherapy.
Tocilizumab is a humanised monoclonal antibody
against the interleukin-6 receptor. It is currently licensed
for the treatment of RA and juvenile idiopathic arthritis
(systemic juvenile idiopathic arthritis and polyarticular
juvenile idiopathic arthritis) in combination with MTX, or
as monotherapy in the case of intolerance to MTX or where
continued treatment with MTX is inappropriate. A positive
recommendation from the National Institute for Health and
Care Excellence (NICE) and Scottish Medicines Consor-
tium (SMC) in 2010 led to TCZ being reimbursed by the
National Health Service (NHS) in the UK [10, 11].
The objective of this cost-effectiveness analysis was to
determine whether the addition of TCZ at the beginning of
a treatment pathway is cost effective in the treatment of
moderate to severe RA.
2 Methods
2.1 Model Overview
The design of the economic analysis followed guidelines
set by the Outcome Measures in Rheumatoid Arthritis
Clinical Trials (OMERACT) Economics Working Group
[12], and the structure was designed to closely represent
clinical practice.
An individual sampling model, designed in MS Excel,
was used to analyse transitions of patients through a
sequence of treatments and, by maintaining patient history,
translate this into economic and QoL outcomes.
The analysis compared the cost effectiveness of differ-
ent strategies containing a sequence of biologic therapies
licensed for use in patients with moderate to severe RA
who had had an inadequate response (IR) to one or more
sDMARDs. Two scenarios were explored separately:
patients contraindicated to MTX and those who were MTX
tolerant.
We defined the current standard of care (SoC) as a
sequence of bDMARDs. In the MTX-tolerant population,
the first treatment was an anti-tumour necrosis factor alpha
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(aTNF) drug; certolizumab pegol has the lowest cost and
therefore we assumed it would be offered first. Ritux-
imab was offered following IR to the first aTNF, in
accordance with the NICE guidance [13]. Thereafter,
bDMARDs were ranked on the basis of their annual
cost—assuming the one with the lowest cost would be
used first. The MTX-contraindicated population model
followed a similar ranking, including only treatments
with a licence for monotherapy. Alternative sequences
for the SoC were explored during the development of the
model; the current one was demonstrated to be the most
conservative.
We considered the addition of TCZ to the current SoC
strategy, and explored its effect at first line and second line
(see Tables 1 and 2).
The characteristics of the model cohort were based on
data from the British Society for Rheumatology Biologics
Register (BSRBR) [14]; they are consistent with the drug
licence and are representative of the UK RA population
(see Table 3). The average patient weight was assumed to
be 70 kg [13, 15]. The analysis time horizon was patient
lifetime.
American College of Rheumatology (ACR) response
probabilities were used to measure response to treatment as
these are readily available from the randomised controlled
trial (RCT) evidence. The model used a 6-month cycle
length, which is in line with the timing of most RCT out-
comes included in the analysis. Disease severity was rep-
resented by changes in Health Assessment Questionnaire
(HAQ) score and Visual Analogue Scale (VAS) pain score,
two surrogate health outcomes which can be translated to
utility scores and ultimately to quality-adjusted life-years
(QALYs). Once patients exhausted all treatments in the
sequence, they moved into palliative care, where they
remained until death. Patients could transition to death on
the basis of a mortality risk adjusted for RA [16]. The
possible transitions and the structure of the model are
illustrated in Fig. 1.
The analysis took a UK NHS perspective, with costs
expressed in 2011/2012 pound sterling and health benefits
measured in QALYs. Both costs and benefits were dis-
counted at an annual rate of 3.5 %, and half-cycle correc-
tion was applied. The performance of alternative treatment
sequences was estimated using incremental cost-effective-
ness ratios (ICERs), defined as the added cost of a given
strategy divided by its added benefit compared with the
next most expensive strategy.
2.2 Treatment Efficacy
Efficacy in the model was determined by response to
treatment, which was subsequently translated to a drop in
HAQ score and change in VAS pain. Responders were
categorised according to their level of ACR response—
Table 1 Strategies for MTX-
contraindicated population
MTX methotrexate, SoC
standard of care, TCZ
tocilizumab
Line of treatment Monotherapy SoC strategy TCZ 1st line (strategy A) TCZ 2nd line (strategy B)
1st Certolizumab pegol TCZ Certolizumab pegol
2nd Etanercept Certolizumab pegol TCZ
3rd Adalimumab Etanercept Etanercept
4th Palliative care Adalimumab Adalimumab
5th Palliative care Palliative care














1st Certolizumab pegol TCZ Certolizumab pegol
2nd Rituximab Certolizumab pegol TCZ
3rd Etanercept Rituximab Rituximab
4th Abatacept Etanercept Etanercept
5th Adalimumab Abatacept Abatacept
6th Infliximab Adalimumab Adalimumab
7th Palliative care Infliximab Infliximab
8th Palliative care Palliative care
Table 3 Baseline characteristics of model cohort
Characteristics Model population Source
Female 77 % [14]
Starting age 58 years
Starting HAQ score 2
Starting VAS pain score 75
Weight 70 kg Assumption
HAQ Health Assessment Questionnaire, VAS Visual Analogue Scale
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ACR00 (no response), ACR20, ACR50 and ACR70. The
proportion of patients achieving each level of response
differed by treatment and was derived through a network
meta-analysis (NMA) of RCT data (see Table 4) [17, 18].
MEDLINE and EMBASE databases were searched
simultaneously for articles published in English, from 1990
to October 2011, using a predefined search strategy. To
allow comparison with the recent TCZ studies, the litera-
ture review focused on studies that included only patients
with sDMARD inadequate response (sDMARD-IR).
Twenty-two relevant studies were identified with ACR
response rates at 24 weeks. Despite some variation in the
patient characteristics across the identified studies (i.e.
duration of disease), there were no observed systematic
differences, indicating the feasibility of the indirect com-
parison. Because of limited data identified for aTNFs used
in monotherapy, response data for all aTNF treatments
were pooled, assuming exchangeability of the efficacy
profile for those agents. An NMA was conducted (Bayesian
framework) to synthesise the identified evidence and to
obtain effect estimates for the bDMARDs. The probability
of ACR response at 24 weeks for the bDMARDs is pre-
sented in Table 4. Rituximab was used in the model in an
aTNF-IR position (in line with its label). Data from a study
on aTNF-IR patients was used for the ACR response
probability with rituximab [18].
Response to treatment was assumed to impact disease
severity and pain, as measured by HAQ and VAS pain
score, respectively. The impact of response to treatment on
HAQ and VAS pain score was assumed to be treatment
independent. Patient-level data from three phase III clinical
trials were pooled and analysed to determine the relation-
ship of ACR response with HAQ (2,204 observations) and
VAS pain score (2,342 observations) (details presented in
Appendix A in the Electronic Supplementary Material)
[19–21]. These studies were selected because their
respective patient characteristics were similar to those
assumed in the economic model and patient-level data were
available for analysis during the model development.
Results suggest a negative correlation between both ACR
response and HAQ score and ACR response and VAS pain
score; that is, the higher the observed ACR response the
greater the drop in HAQ and VAS pain scores (see
Table 4).
The relationship between ACR response, HAQ and VAS
pain was assumed to be the same across all treatments. A
patient’s disease was assumed to remain stable whilst on
biologic treatment and progress whilst on palliative care,
Fig. 1 Model structure, health states and transitions. ACR American College of Rheumatology, HAQ Health Assessment Questionnaire, QoL
quality of life, sDMARD synthetic disease-modifying anti-rheumatic drugs, VAS Visual Analogue Scale
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Table 4 Key model parameters and assumptions
Variable Value Description (source)
ACR response (%), probability of ACR20/50/70
Combination therapy
aTNF ? MTX 72/52/17 Generated from NMA [17]
TCZ ? MTX 67/51/23
Abatacept ? MTX 64/42/13
Infliximab 72/52/17
Palliative care (placebo rates) 33/16/3
Rituximab ? MTX 51/27/12 Unadjusted rates from Cohen et al. [18]
Monotherapy (MTX contraindicated)
aTNF 50/27/12 Generated from NMA [17]
TCZ 66/46/24
Palliative care (placebo rates) 17/6/1
Average decrease in HAQ by ACR response category (SE)
\20 0.14 (0.02) Post hoc analysis [19–21]. See Appendix A in
the Electronic Supplementary MaterialC20 and \50 0.46 (0.02)
C50 and \70 0.68 (0.03)
C70 0.90 (0.03)
Average decrease in VAS pain score by ACR category (SE)
\20 4.02 (0.79) Post-hoc analysis [19–21]. See Appendix A
in the Electronic Supplementary MaterialC20 and \50 23.97 (0.86)
C50 and \70 36.00 (0.95)
C70 45.96 (1.26)
Average VAS pain score in palliative care 55 (1.28) Clinical expert opinion
Probability of discontinuation from treatment
bDMARD-naı¨ve (loglogistic model)
Scale 0.76262 Based on analysis of SCQM-RA data
See variance covariance matrix in Appendix




Scale 1.44484 Based on analysis of SCQM-RA data. See




Probability of serious infection (SE)
Certolizumab pegol 0.113 (0.074) [26]
bDMARD (excluding certolizumab pegol) 0.035 (0.0048) [26]
Average 6-monthly HAQ score decrease on treatment (SE)
bDMARDs 0 (0.0057) [22]
sDMARDs 0.0225 (0.0019) [22]
Palliative care 0.03 [22]
Utility multiplier for AEs (synthesised using methods from Ara and Brazier [34])
bDMARDs 0.9858 [33]
Palliative care/MTX-combination model 0.9700 Appendix C and D in the Electronic
Supplementary Material
Palliative care/MTX contraindicated 0.9717 Appendix C and D in the Electronic
Supplementary Material
ACR American College of Rheumatology, AEs adverse events, aTNF anti-tumour necrosis factor alpha, bDMARD biologic disease-modifying
anti-rheumatic drug, bDMARD-IR biologic disease-modifying anti-rheumatic drug inadequate response, HAQ Health Assessment Questionnaire,
MTX methotrexate, NMA network meta-analysis, SE standard error, sDMARD synthetic disease-modifying anti-rheumatic drug, TCZ toc-
ilizumab, VAS Visual Analogue Scale
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an approach taken by previous evidence reimbursement
submissions in the UK [10, 11] and a recent NICE multiple
technology appraisal [22] (see Table 4). The level of VAS
pain for patients in palliative care was assumed to be 55, on
the basis of clinical expert opinion (AF, TH).
2.3 Treatment Discontinuation
Since patients were assumed to try all drugs in a given
strategy, treatment discontinuation became an important
driver of the model outcomes. An analysis of a large bi-
ologics data registry (n = 1,464 without rituximab sample)
in Europe (Swiss Clinical Quality Management in Rheu-
matic Diseases [SCQM-RA]) showed that discontinuation
can be response related. Since the SCQM-RA data set did
not have ACR response evidence for many patients, we
used European League Against Rheumatism (EULAR)
response data as a proxy for this input [23]. A range of
parametric survival models (Weibull, exponential, loglo-
gistic, lognormal) were explored. We selected the best
fitting model based on Akaike Information Criteria (AIC)
and visual inspection of the resulting curves against the
SCQM-RA Kaplan–Meier curves and UK observational
data [24]. The loglogistic model had the best fit for
bDMARD-naive patients, and the lognormal model for the
bDMARD-IR patients. These were used as a base case
while alternative models were tested in the sensitivity
analysis (details of the treatment discontinuation analysis
are presented in Appendix B in the Electronic Supple-
mentary Material).
Little evidence exists on the long-term sustained benefit
of treatment after patients withdraw because of a lack of
efficacy. Some evidence suggests that a ‘‘rebound’’ occurs
when therapy is withdrawn [25]. In our analysis, we
assumed that HAQ worsening was equal to the initial HAQ
improvement and that it occurred immediately at the point
of withdrawal. That is, patients who withdrew because of a
lack of efficacy immediately returned to their starting HAQ
score, until they began their next treatment.
2.4 Treatment Safety
The safety of biologic treatments was derived from a recent
systematic review and NMA [26]. The pooled results for all
biologic treatments indicated that the odds of serious
infection (defined as those associated with death, hospi-
talisation and use of intravenous antibiotics) were signifi-
cantly greater than for control [odds ratio 1.37, 95 %
confidence interval (CI) 1.04–1.82]. Singh and colleagues
[26] also presented results for each individual biologic
therapy, among which only the odds ratio for certolizumab
pegol reached statistical significance (4.75, 95 % CI
1.52–18.65). In order to reflect this difference, the
probability of serious infection for certolizumab pegol was
derived from its individual odds ratio (4.75) and for all
other biologics from the generic odds ratio (1.37). The
resulting absolute risks, which were applied at every cycle
whilst on a given treatment, are shown in Table 4.
The safety of drugs typically used as part of palliative
care was also reviewed. A survey of clinical experts indi-
cated that most patients who have failed all previous bio-
logic treatments would be on a mixture of therapies
including glucocorticoids and sDMARDs for disease
management, selective and non-selective NSAIDs for
symptom control, and opioids and analgesics for pain
relief. Reviews of those treatments indicated that the most
frequent adverse events (AEs) include dyspepsia, nausea,
constipation, infections, headaches, dizziness, skin rash/
allergy and alopecia [19, 27–31]. The incidence of these
events was combined with associated costs and utilities for
inclusion in the economic model (details of the palliative
care survey are presented in Appendix C in the Electronic
Supplementary Material).
2.5 Health-Related Quality of Life
Change in HAQ, VAS pain and the associated utility gain
were used in the model to determine the impact of treat-
ment on overall health. Estimates of utility gain were cal-
culated using a regression model for mapping HAQ scores
to the EuroQol 5-Dimensions (EQ-5D) score [32]. This
model represents an improvement to previous mapping
algorithms in that it accommodates not only the ceiling
effect and the gap in the data but also the observed multi-
modality in EQ-5D. It also considers the effect of VAS
pain, which is one of the most heavily weighted items in
the EQ-5D. The EQ-5D score for each simulated individual
was estimated based on the Alava model, the simulated
HAQ score which is linked to ACR response, VAS pain
scores from the clinical trials (Table 4), and patient age in
each cycle.
For the disutility from serious AEs while on a bDM-
ARD, we reviewed six of the largest studies identified from
the Cochrane safety review [26]. We found that the most
common and significant serious infection was pneumonia
[19, 27–31]. A utility for pneumonia was identified in the
literature—0.21 [33]; it was adjusted for the expected
duration of the event (7 days) and the baseline age and
gender of the Sisk et al. [33] cohort. The resulting utility
multiplier (0.9858) was combined with the incidence of
serious infections and applied to the baseline utility derived
from the Alava model.
Disutility for AEs associated with palliative care was
identified through a targeted review of published economic
evaluations, and multipliers were derived in the same
fashion (details in Appendix D in the Electronic
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Supplementary Material). Utility multipliers were then
combined with the incidence of each AE to estimate a
weighted average utility multiplier for palliative care; note
that this is slightly different for patients receiving MTX
and those for whom MTX is contraindicated (Table 4).
2.6 Treatment-Related Costs
The treatment cost for each drug was sourced from the
British National Formulary [35], and the dose schedules for
each treatment were taken from the electronic Medicines
Compendium (eMC) website [36] (see Table 5). For
weight-based dosing, the average patient was assumed to
weigh 70 kg. A patient access scheme (PAS) for certo-
lizumab pegol was considered in the calculations; the
manufacturer provides the first 12 weeks (ten pre-loaded
200-mg syringes) free of charge to all patients starting
treatment.
Ten per cent of subcutaneous injection treatment was
assumed to be administered by a district nurse. Monitoring
patients who receive subcutaneously injected medicines
was assumed to involve an outpatient visit or a general
practitioner visit and certain examinations and tests, such
as full blood count, erythrocyte sedimentation rate,
C-reactive protein, liver function test, chest X-ray, urea,
electrolytes and creatinine. The resource use assumed in
this analysis was consistent with previous evidence reim-
bursement submissions [10, 11]. The cost of administering
and monitoring intravenous drugs was assumed to be
£171.33 per infusion [37].
The drug cost for palliative care was based on a
weighted average of treatments (glucocorticoids, sDM-
ARDs, selective and non-selective NSAIDs, opioids). No
costs were assumed for administering palliative care, but
monitoring costs were assumed to be high, driven by a
greater number of primary and secondary care visits and
blood tests.
2.7 Adverse Event-Related Costs
The cost for pneumonia was sourced from the NHS ref-
erence costs [38]. The costs of other AEs associated with
drugs used in palliative care included those of dyspepsia
and constipation. No costs were reported for experiencing
nausea, hypertension, headaches, dizziness, skin rash/
allergy or alopecia. These were synthesised with incidence
figures and relative usage of different drugs from the expert
survey to arrive at a set of values for palliative care (see
Table 5).
2.8 Disease-Related Costs
In addition to treatments received and the monitoring
included therein, many patients were assumed to require
inpatient care associated with their RA. The model
assumed six different bands of HAQ score to reflect mild,
Table 5 Treatment, AE and
disease-related costs





Combination therapy (total cost first 6 months/subsequent cycles)
Adalimumab (40 mg every 2 weeks) ? MTX £6,324/£5,261
Certolizumab pegol (200 mg every 2 weeks) ? MTX £4,070/£5,331
Etanercept (50 mg every week) ? MTX £6,429/£5,366
TCZ (8 mg/kg every 4 weeks) ? MTX £4,776/£4,776
Abatacept (750 mg every 4 weeks) ? MTX £7,015/£7,015
Infliximab (3 mg/kg every 8 weeks) ? MTX £3,425/£3,425




Combined AEs for palliative care
Combination therapy model £168
Monotherapy model £141
Patient condition-related costs
HAQ \0.5 £62 (0.26)
HAQ C0.6 and \1.0 £31 (0.13)
HAQ C1.0 and \1.5 £122 (0.51)
HAQ C1.5 and \2.0 £173 (0.72)
HAQ C2.0 and \2.6 £446 (1.86)
HAQ C2.6 and \3.0 £998 (4.16)
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moderate and severe disease [39, 40]. Data from the Nor-
folk Arthritis Register (NOAR) in the UK were analysed
such that mean days in hospital over a 12-month period
could be estimated for each HAQ score category. Based on
a cost of £240 per inpatient day, each HAQ score category
was assigned a cost (see Table 5).
2.9 Sensitivity Analysis and Parameter Uncertainty
One-way sensitivity analysis (OWSA) was performed to
identify the model drivers and the magnitude of their
impact on the model results. In order to explore uncertainty
around the model’s input, probabilistic sensitivity analysis
(PSA) was also performed (1,000 samples).
3 Results
Aggregate results were based on 3,000 simulations of
hypothetical patient pathways. Table 6 displays the cost-
effectiveness results for the monotherapy strategies. The
estimated total cost for the SoC strategy was £139,000; the
total QALYs accrued were 8.0162 over an average
21.5 years in the model. The addition of TCZ to the SoC
after sDMARD-IR increased the estimated total cost to
£143,000 and produced 8.4987 QALYs. In the TCZ strat-
egy, time on biologic treatment was extended by an aver-
age of 2.5 years compared with the SoC strategy. The
ICER was estimated to be £7,300 per QALY gained. If
TCZ was added in the sequence in later positions (e.g.
second line), the costs and QALYs increased. The ICER
was estimated to be £11,400 per QALY gained.
Table 7 presents the cost-effectiveness results for the
combination treatment strategies. The three strategies were
similar in terms of total costs and total QALYs gained. The
number of patients receiving palliative care was reduced
substantially across all comparator strategies, on average
by 3 and 6 % of simulated individuals on TCZ or SoC
strategy, respectively. In the SoC strategy, patients were
estimated to stay on biologics for 21 years. In the strategy
by which TCZ was offered first after sDMARD-IR, patients
stayed on biologics for almost the duration of the model
(21.5 years on average).
The OWSA is presented in Tables 8 and 9. Respective
changes to model parameters have the same impact in both
the monotherapy and the MTX-combination analyses.
Overall, the model was sensitive to changes in the TCZ
treatment cost. Changes to the assumed patient weight
affected the TCZ cost and consequently the final ICER.
Given that the results between the two comparator strate-
gies are similar in the combination model, the increase in
cost changes the conclusion of the cost-effectiveness ana-
lysis; the TCZ strategy no longer produces cost-savings and
the result is a high ICER.
Assumptions around palliative care did not have a sub-
stantial impact on the overall cost-effectiveness results;
neither did changes to the assumptions on AEs of biologics
or ACR response rates [9]. The choice of discontinuation
risk (time dependent or constant) and the choice of QoL
mapping model had a moderate effect on the model results.
Figures 2 and 3 present the results of the PSA with cost-
effectiveness acceptability curves for the monotherapy and
the combination with MTX analyses. In both cases, the
probability of cost effectiveness was estimated to be higher
when TCZ was added first in the treatment sequence.
Details of the parameters, ranges and distributions assumed
for the PSA are presented in Appendix E in the Electronic
Supplementary Material.
4 Discussion
To our knowledge, this is the first analysis investigating the
cost effectiveness of adding TCZ to SoC, compared as
monotherapy or in combination with MTX, in treating
adults with moderate to severe RA in the UK. The analysis
was based on the reimbursement application to NICE in the
UK; all assumptions follow the NICE reference case [41].
Our economic evaluation synthesised evidence of
patient characteristics of a UK population [14], evidence
from an NMA of randomised clinical trials for drug effi-
cacy [17], registry data analysis for discontinuation
(SCQM-RA), and cost estimates from the NHS UK per-
spective, with a PAS where applicable. With regard to QoL
estimates, as noted in the ‘‘Methods’’ section, the analysis
used a mapping model that the authors here consider an
improvement on previous algorithms [25, 42–44].
In both populations (monotherapy and MTX combina-
tion), the addition of TCZ to the current treatment sequence
in the UK appeared to be a cost-effective strategy. How-
ever, its impact in QALYs gained was more pronounced in
the monotherapy than in the combination model. Part of
this was due to the additional benefits in QALYs driven by
TCZ efficacy, and another part was due to the displacing of







SoC £130,736.86 £139,008.09 8.0162
TCZ 1st line £136,157.48 £142,525.23 8.4987 £7,289.63
TCZ 2nd line £137,686.19 £144,744.15 8.5194 £11,400.26
ICER incremental cost-effectiveness ratio, QALY quality-adjusted
life-year, SoC standard of care, TCZ tocilizumab
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time on palliative care. Since the latter is more likely to
happen in the monotherapy model, where there are fewer
treatment options for an RA patient, the impact is more
pronounced there and less in the combination treatment
model, where, on average, patients will spend significantly
less time on palliative care, in the last months of their lives.
The assumptions on the risk of discontinuation were an
important driver of the model, especially since we assumed
that patients would try all treatments in a strategy. We ran a
post hoc analysis of observational data to estimate the
probability of discontinuation (assumed time dependent). It
is a limitation of this study that we did not have access to a
UK registry for this analysis, and therefore the input data
could suffer from generalising from a Swiss cohort of
patients. Nevertheless, when we compared the data with
evidence from Hyrich et al. [14] and Soliman et al. [24]
from the UK, the resulting risk was found to be similar.
Another limitation regarding the SCQM-RA data analysis
is that because of a very small number of ACR response
data, we used EULAR response as a proxy.
Our model used the ACR response criteria to weigh the
benefit of treatment (HAQ, VAS pain scores and QALYs).
Ideally, the model could use Disease Activity Scores using
28 joints or EULAR response, in line with NICE decision
rules. The use of ACR response criteria ensures a wider
choice of studies that inform our NMA and, on balance we
considered this to be more important for the economic
model input.
With regard to the treatment cost calculations, after the
addition of administration and monitoring costs, the
Table 7 Base-case cost-effectiveness results for combination therapy strategies
Total drug costs Total costs Total QALYs ICER
SoC £144,555.66 £150,665.03 8.8609 Dominated by TCZ 1st line
TCZ 1st line £142,337.63 £147,640.97 8.9050 Dominant
TCZ 2nd line £144,129.33 £150,127.31 8.8983 Dominated by TCZ 1st line
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, SoC standard of care, TCZ tocilizumab
Table 8 One-way sensitivity analysis of cost-effectiveness results for monotherapy strategies
Scenario Description SoC TCZ strategy ICER
Total cost Total QALYs Total cost Total QALYs
Base case Base case—TCZ at 1st line £139,008.09 8.016 £142,525.23 8.499 £7,289.63
Scenario 1 Using Weibull model for discontinuation
(SCQM-RA)
£134,751.18 7.834 £140,255.64 8.395 £9,816.87
Scenario 2 Using constant discontinuation risks
(SCQM-RA)
£125,168.26 7.334 £133,266.16 8.003 £12,095.97
Scenario 3 Assume no cost for palliative care £137,002.34 8.016 £141,508.25 8.499 £9,338.92
Scenario 4 Palliative care cost equals the average cost
of all biologics
£160,654.65 8.016 £153,500.87 8.499 TCZ dominates
Scenario 5 Assume no disutility for palliative care: baseline
HAQ score is 0
£138,815.92 8.351 £142,453.87 8.658 £11,843.09
Scenario 6 Patients’ weight at baseline is 60 kg £139,008.09 8.016 £136,191.31 8.499 TCZ dominates
Scenario 7 Patients’ weight at baseline is 80 kg £139,008.09 8.016 £148,859.16 8.499 £20,417.30
Scenario 8 bDMARDs assume no AE disutility or cost £135,515.90 8.096 £139,530.04 8.539 £9,057.90
Scenario 9 Use QoL equation from Bansback et al. [43];
QoL = 0.76 - 0.28 9 HAQ ? 0.05 9 female
£139,008.09 4.354 £142,525.23 4.827 £7,426.08
Scenario 10 Use QoL equation from MabThera analysis [42];
QoL = 0.862 - 0.327 9 HAQ
£139,008.09 4.085 £142,525.23 4.625 £6,506.64
Scenario 11 Use QoL equation from Ducournau et al. [44];
QoL = 0.8229 - 0.1125 9 HAQ -
0.06874 9 HAQ2
£139,008.09 5.731 £142,525.23 6.339 £5,784.48
Scenario 12 ACR data from NICE Assessment Report [9] £139,681.68 8.051 £143,248.67 8.509 £7,782.19
ACR American College of Rheumatology, AE adverse event, bDMARDs biologic disease-modifying anti-rheumatic drugs, HAQ Health
Assessment Questionnaire, ICER incremental cost-effectiveness ratio, NICE National Institute of Health and Care Excellence, QALY quality-
adjusted life-year, QoL quality of life, SCQM-RA Swiss Clinical Quality Management in Rheumatic Diseases, SoC standard of care, TCZ
tocilizumab
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average total cost for a biologic was just over £10,000 per
year. Since our comparison was one of treatment strategies,
it was the cost of TCZ (solely based on patients’ weight)
that had the most impact on the cost-effectiveness results—
as shown from the sensitivity analysis.
The research conducted on the cost of palliative care
(patient monitoring and safety) added to the completeness
of the overall analysis, but had no notable impact on the
model results; its overall cost was very low compared with
the add-on bDMARD (TCZ). At the development phase of
the palliative care survey, we anticipated greater conver-
gence amongst the individual responses. However, we
found large variation amongst responses, and this prohib-
ited any statistical analysis or summarisation of the survey
findings. This could be due to methodological issues: the
type of questions, the format of the interview, the rounds of
revision or clarifications, etc. It also appears likely that
since clinicians are less and less likely to face those cases
Table 9 One-way sensitivity analysis of cost-effectiveness results for combination therapy strategies
Scenario Description SoC TCZ strategy ICER
Total cost Total QALYs Total cost Total QALYs
Base case Base case—TCZ at 1st line £150,665.03 8.861 £147,640.97 8.905 TCZ dominates
Scenario 1 Using Weibull model for discontinuation
(SCQM-RA)
£151,349.35 8.854 £148,061.14 8.923 TCZ dominates
Scenario 2 Using constant discontinuation risks
(SCQM-RA)
£148,216.33 8.687 £146,987.86 8.814 TCZ dominates
Scenario 3 Assume no cost for palliative care £150,500.20 8.861 £147,571.42 8.905 TCZ dominates
Scenario 4 Palliative care cost equals the average
cost of all biologics
£152,807.51 8.861 £148,544.93 8.905 TCZ dominates
Scenario 5 Assume no disutility for palliative care:
baseline HAQ score is 0
£150,655.89 8.888 £147,639.40 8.916 TCZ dominates
Scenario 6 Patients’ weight at baseline is 60 kg £150,391.10 8.861 £141,165.45 8.905 TCZ dominates
Scenario 7 Patients’ weight at baseline is 80 kg £150,938.95 8.861 £154,116.48 8.905 £72,107.33
Scenario 8 bDMARDs assume no AE disutility or cost £146,780.20 8.869 £144,432.09 8.912 TCZ dominates
Scenario 9 Use QoL equation from Bansback et al. [43];
QoL = 0.76 - 0.28 9 HAQ ? 0.05 9 female
£150,665.03 5.250 £147,640.97 5.326 TCZ dominates
Scenario 10 Use QoL equation from MabThera analysis [42];
QoL = 0.862 - 0.327 9 HAQ
£150,665.03 5.105 £147,640.97 5.194 TCZ dominates
Scenario 11 Use QoL equation from Ducournau et al. [44];
QoL = 0.8229 - 0.1125 9 HAQ
- 0.06874 9 HAQ2
£150,665.03 6.884 £147,640.97 6.972 TCZ dominates
Scenario 12 ACR data from NICE Assessment Report [9] £149,735.11 8.912 £147,251.97 8.935 TCZ dominates
ACR American College of Rheumatology, AE adverse event, bDMARDs biologic disease-modifying anti-rheumatic drugs, HAQ Health
Assessment Questionnaire, ICER incremental cost-effectiveness ratio, NICE National Institute of Health and Care Excellence, QALY quality-





standard of care, TCZ
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(patients who run out of treatment options), they tend to
consider extreme examples in their responses. Furthermore,
clinical practice is often determined by the number of
treatments available to clinicians, which may vary a lot
from one jurisdiction to another. Since the data survey on
palliative care involved only six clinical experts and
responses varied significantly, the results should be inter-
preted with caution.
Further research is necessary for a number of parameters
of the economic model. In particular, with regard to dis-
continuation, one could explore different hypotheses that
test treatment-related discontinuation, age, gender and
other patient characteristics. Our analysis assumed that
discontinuation was response related, which fitted well
with our model structure and produced plausible results.
Furthermore, as new and more bDMARDs become avail-
able to RA patients, research could identify subgroups
where treatments are more efficacious, potentially pro-
ducing more cost savings for the healthcare provider.
Overall, although we found that the model was sensitive to
changes that affect the cost of TCZ and time on treatment, we
believe that further refinement of those parameters would not
significantly change the analysis conclusions.
5 Conclusion
The addition of TCZ to the SoC is estimated to be a cost-
effective strategy in the treatment of patients with moderate
to severe RA. In 1,000 samples in the PSA, the strategy
with TCZ at first line had a higher estimated probability of
being cost effective than TCZ at second line.
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